Summary

Veterinary Molecular Diagnostics Market – Scope of Report
TMR’s report on the global veterinary molecular diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global veterinary molecular diagnostics market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global veterinary molecular diagnostics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the veterinary molecular diagnostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global veterinary molecular diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global veterinary molecular diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global veterinary molecular diagnostics market.

The report delves into the competitive landscape of the global veterinary molecular diagnostics market. Key players operating in the global veterinary molecular diagnostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global veterinary molecular diagnostics market profiled in this report.

Key Questions Answered in Global veterinary molecular diagnostics market Report
• What is the sales/revenue generated by wearable injectors across all regions during the forecast period?
• What are the opportunities in the global veterinary molecular diagnostics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Veterinary Molecular Diagnostics Market – Research Objectives and Research Approach
The comprehensive report on the global veterinary molecular diagnostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global veterinary molecular diagnostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global veterinary molecular diagnostics market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Veterinary Molecular Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Veterinary Molecular Diagnostics Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Veterinary Molecular Diagnostics Market Analysis and Forecast, by Product Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product Type, 2017–2031
6.3.1. Instruments & Software
6.3.2. Kits & Reagents
6.3.3. Services
6.4. Market Attractiveness, by Product Type
7. Global Veterinary Molecular Diagnostics Market Analysis and Forecast, by Technology
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Technology, 2017–2031
7.3.1. Conventional PCR
7.3.2. Singleplex PCR
7.3.3. Multiplex PCR
7.3.4. Real-time PCR
7.3.5. Others
7.3.6. 7.4 Market Attractiveness, by Technology
8. Global Veterinary Molecular Diagnostics Market Analysis and Forecast, By Disease Type
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, By Disease Type, 2017–2031
8.3.1. Vector-borne Diseases
8.3.2. Respiratory Pathogens
8.3.3. Diarrhea Pathogens
8.3.4. Others
8.4. Market Attractiveness, By Disease Type
9. Global Veterinary Molecular Diagnostics Market Analysis and Forecast, by Animal Type
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Animal Type, 2017–2031
9.3.1. Companion Animal
9.3.2. Livestock Animal
9.4. Market Attractiveness, by Animal Type
10. Global Veterinary Molecular Diagnostics Market Analysis and Forecast, by End-user
10.1. Introduction and Definitions
10.2. Key Findings/Developments
10.3. Market Value Forecast, by End-user, 2017–2031
10.3.1. Hospitals/Clinics
10.3.2. Reference Laboratories
10.4. Market Attractiveness, by End-user
11. Global Veterinary Molecular Diagnostics Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region, 2017–2031
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness, by Region
12. North America Veterinary Molecular Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product Type, 2017–2031
12.2.1. Instruments & Software
12.2.2. Kits & Reagents
12.2.3. Services
12.3. Market Attractiveness, by Product Type
12.4. Market Value Forecast, by Technology, 2017–2031
12.4.1. Conventional PCR
12.4.2. Singleplex PCR
12.4.3. Multiplex PCR
12.4.4. Real-time PCR
12.4.5. Others
12.5. Market Attractiveness, by Technology
12.6. Market Value Forecast, By Disease Type, 2017–2031
12.6.1. Vector-borne Diseases
12.6.2. Respiratory Pathogens
12.6.3. Diarrhea Pathogens
12.6.4. Others
12.7. Market Attractiveness, By Disease Type
12.8. Market Value Forecast, by Animal Type, 2017–2031
12.8.1. Companion Animal
12.8.2. Livestock Animal
12.9. Market Attractiveness, by Animal Type
12.10. Market Value Forecast, by User End-user, 2017–2031
12.10.1. Hospitals/Clinics
12.10.2. Reference Laboratories
12.11. Market Attractiveness, by End-user
12.12. Market Value Forecast, by Country/Sub-region, 2017–2031
12.12.1. U.S.
12.12.2. Canada
12.13. Market Attractiveness Analysis
12.13.1. By Product Type
12.13.2. By Technology
12.13.3. By Disease Type
12.13.4. By Animal Type
12.13.5. By End-user
12.13.6. By Country
13. Europe Veterinary Molecular Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product Type, 2017–2031
13.2.1. Instruments & Software
13.2.2. Kits & Reagents
13.2.3. Services
13.3. Market Attractiveness, by Product Type
13.4. Market Value Forecast, by Technology, 2017–2031
13.4.1. Conventional PCR
13.4.2. Singleplex PCR
13.4.3. Multiplex PCR
13.4.4. Real-time PCR
13.4.5. Others
13.5. Market Attractiveness, by Technology
13.6. Market Value Forecast, By Disease Type, 2017–2031
13.6.1. Vector-borne Diseases
13.6.2. Respiratory Pathogens
13.6.3. Diarrhea Pathogens
13.6.4. Others
13.7. Market Attractiveness, By Disease Type
13.8. Market Value Forecast, by Animal Type, 2017–2031
13.8.1. Companion Animal
13.8.2. Livestock Animal
13.9. Market Attractiveness, by Animal Type
13.10. Market Value Forecast, by User End-user, 2017–2031
13.10.1. Hospitals/Clinics
13.10.2. Reference Laboratories
13.11. Market Attractiveness, by End-user
13.12. Market Value Forecast, by Country/Sub-region, 2017–2031
13.12.1. Germany
13.12.2. U.K.
13.12.3. France
13.12.4. Italy
13.12.5. Spain
13.12.6. Rest of Europe
13.13. Market Attractiveness Analysis
13.13.1. By Product Type
13.13.2. By Technology
13.13.3. By Disease Type
13.13.4. By Animal Type
13.13.5. By End-user
13.13.6. By Country/Sub-region
14. Asia Pacific Veterinary Molecular Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product Type, 2017–2031
14.2.1. Instruments & Software
14.2.2. Kits & Reagents
14.2.3. Services
14.3. Market Attractiveness, by Product Type
14.4. Market Value Forecast, by Technology, 2017–2031
14.4.1. Conventional PCR
14.4.2. Singleplex PCR
14.4.3. Multiplex PCR
14.4.4. Real-time PCR
14.4.5. Others
14.5. Market Attractiveness, by Technology
14.6. Market Value Forecast, By Disease Type, 2017–2031
14.6.1. Vector-borne Diseases
14.6.2. Respiratory Pathogens
14.6.3. Diarrhea Pathogens
14.6.4. Others
14.7. Market Attractiveness, By Disease Type
14.8. Market Value Forecast, by Animal Type, 2017–2031
14.8.1. Companion Animal
14.8.2. Livestock Animal
14.9. Market Attractiveness, by Animal Type
14.10. Market Value Forecast, by User End-user, 2017–2031
14.10.1. Hospitals/Clinics
14.10.2. Reference Laboratories
14.11. Market Attractiveness, by End-user
14.12. Market Value Forecast, by Country/Sub-region, 2017–2031
14.12.1. China
14.12.2. Japan
14.12.3. India
14.12.4. Australia & New Zealand
14.12.5. Rest of Asia Pacific
14.13. Market Attractiveness Analysis
14.13.1. By Product Type
14.13.2. By Technology
14.13.3. By Disease Type
14.13.4. By Animal Type
14.13.5. By End-user
14.13.6. By Country/Sub-region
15. Latin America Veterinary Molecular Diagnostics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product Type, 2017–2031
15.2.1. Instruments & Software
15.2.2. Kits & Reagents
15.2.3. Services
15.3. Market Attractiveness, by Product Type
15.4. Market Value Forecast, by Technology, 2017–2031
15.4.1. Conventional PCR
15.4.2. Singleplex PCR
15.4.3. Multiplex PCR
15.4.4. Real-time PCR
15.4.5. Others
15.5. Market Attractiveness, by Technology
15.6. Market Value Forecast, By Disease Type, 2017–2031
15.6.1. Vector-borne Diseases
15.6.2. Respiratory Pathogens
15.6.3. Diarrhea Pathogens
15.6.4. Others
15.7. Market Attractiveness, By Disease Type
15.8. Market Value Forecast, by Animal Type, 2017–2031
15.8.1. Companion Animal
15.8.2. Livestock Animal
15.9. Market Attractiveness, by Animal Type
15.10. Market Value Forecast, by User End-user, 2017–2031
15.10.1. Hospitals/Clinics
15.10.2. Reference Laboratories
15.11. Market Attractiveness, by End-user
15.12. Market Value Forecast, by Country/Sub-region, 2017–2031
15.12.1. Brazil
15.12.2. Mexico
15.12.3. Rest of Latin America
15.13. Market Attractiveness Analysis
15.13.1. By Product Type
15.13.2. By Technology
15.13.3. By Disease Type
15.13.4. By Animal Type
15.13.5. By End-user
15.13.6. By Country/Sub-region
16. Middle East & Africa Veterinary Molecular Diagnostics Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Product Type, 2017–2031
16.2.1. Instruments & Software
16.2.2. Kits & Reagents
16.2.3. Services
16.3. Market Attractiveness, by Product Type
16.4. Market Value Forecast, by Technology, 2017–2031
16.4.1. Conventional PCR
16.4.2. Singleplex PCR
16.4.3. Multiplex PCR
16.4.4. Real-time PCR
16.4.5. Others
16.5. Market Attractiveness, by Technology
16.6. Market Value Forecast, By Disease Type, 2017–2031
16.6.1. Vector-borne Diseases
16.6.2. Respiratory Pathogens
16.6.3. Diarrhea Pathogens
16.6.4. Others
16.7. Market Attractiveness, By Disease Type
16.8. Market Value Forecast, by Animal Type, 2017–2031
16.8.1. Companion Animal
16.8.2. Livestock Animal
16.9. Market Attractiveness, by Animal Type
16.10. Market Value Forecast, by User End-user, 2017–2031
16.10.1. Hospitals/Clinics
16.10.2. Reference Laboratories
16.11. Market Attractiveness, by End-user
16.12. Market Value Forecast, by Country/Sub-region, 2017–2031
16.12.1. GCC Countries
16.12.2. South Africa
16.12.3. Rest of Middle East & Africa
16.13. Market Attractiveness Analysis
16.13.1. By Product Type
16.13.2. By Technology
16.13.3. By Disease Type
16.13.4. By Animal Type
16.13.5. By End-user
16.13.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (By Tier and Size of Companies)
17.2. Market Share Analysis, by Company (2022)
17.3. Company Profiles
17.3.1. IDEXX Laboratories, Inc.
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Product Portfolio
17.3.1.3. Financial Overview
17.3.1.4. SWOT Analysis
17.3.1.5. Strategic Overview
17.3.2. Thermo Fisher Scientific, Inc.
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Product Portfolio
17.3.2.3. Financial Overview
17.3.2.4. SWOT Analysis
17.3.2.5. Strategic Overview
17.3.3. Zoetis, Inc.
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Product Portfolio
17.3.3.3. Financial Overview
17.3.3.4. SWOT Analysis
17.3.3.5. Strategic Overview
17.3.4. Neogen Corporation
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Product Portfolio
17.3.4.3. Financial Overview
17.3.4.4. SWOT Analysis
17.3.4.5. Strategic Overview
17.3.5. bioMérieux SA
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Product Portfolio
17.3.5.3. Financial Overview
17.3.5.4. SWOT Analysis
17.3.5.5. Strategic Overview
17.3.6. QIAGEN N.V.
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Product Portfolio
17.3.6.3. Financial Overview
17.3.6.4. SWOT Analysis
17.3.6.5. Strategic Overview
17.3.7. Biomedica Medizinprodukte GmbH
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Product Portfolio
17.3.7.3. Financial Overview
17.3.7.4. SWOT Analysis
17.3.7.5. Strategic Overview
17.3.8. Bioneer
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Product Portfolio
17.3.8.3. Financial Overview
17.3.8.4. SWOT Analysis
17.3.8.5. Strategic Overview
17.3.9. Mars, Incorporated
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Product Portfolio
17.3.9.3. Financial Overview
17.3.9.4. SWOT Analysis
17.3.9.5. Strategic Overview
17.3.10. Innovative Diagnostics
17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.10.2. Product Portfolio
17.3.10.3. Financial Overview
17.3.10.4. SWOT Analysis
17.3.10.5. Strategic Overview